This mAb is one we first made @VUMC_Vaccines . For more details, here is the original manuscript describing it (and many others). Glad to see this important step!
https://t.co/UQRDfxbZWn
Our @CCTSI director of Resources and Services, @kmess44 of @COpedsID, led a newly published study with @VogtVirusLab showing how children's #immune responses to viruses like EVD68, flu, and RSV changed during and after #COVID-19 safety measures. ▶️ https://t.co/q5mIwZJrFo
A Commentary by @SCauchemez highlights the importance of population level serologic surveillance, demonstrated by the PREMISE approach, to a paradigm shift in global infectious disease surveillance
https://t.co/lah4Y4rEey
Couldn’t agree more with @kmess44 here. This work is cool in like four different ways. Learning about EV-D68, yes, but also so many more viruses. Strengthening prediction abilities for viruses. And feeding into mAb and vaccine prep. I love it all ❤️
Leading this PREMISE project w @Peds_Hai_D & @VogtVirusLab has been one of the highlights of my career. So many amazing ppl worked together to generate this novel data from a unique immunoepidemiologic approach to infectious disease surveillance. Excited to share our 1st paper!👇
I’m pumped to see this work in print! Congrats to the @hdtbio crew on a very cool EV-D68 vaccine. This was a fantastic way to debut our #AFM mouse model. Glad you brought us on and congrats on getting the cover, to boot!
🧵 New in @ScienceTM and on the cover! https://t.co/zbaH92M1Vu After developing RNA vaccines for several different enveloped viruses, we realized that no one had done so for nonenveloped viruses. In this paper, we sought to do just that, with a focus on a prototype picornavirus.
Since they don't link to it in the press release, this is the manuscript describing the mAb if you are interested in a deeper dive: https://t.co/UQRDfxbZWn
A long time coming and very exciting: one of our anti-EV-D68 mAbs is entering clinical trials!
NIH-Sponsored Trial of Enterovirus D68 Therapeutic Begins | NIAID: National Institute of Allergy and Infectious Diseases https://t.co/PErbitbib6
NIAID: NIH-Sponsored Trial of Enterovirus D68 Therapeutic Begins. Years of work by @VogtVirusLab & others have led to the development of EV-D68 monoclonal Abs, studied in🐁, now moving to 1st in human trials. #thisisAFM https://t.co/bIUTJyM05C
Ars Technica: The mystery behind the uncoupling of enterovirus D68 #EVD68 and acute flaccid myelitis in the US in 2022, featuring @COpedsID's @kmess44@VogtVirusLab@Reovirus discussing the nuances and uncertainty surrounding this important observation
https://t.co/uic1nV0cgE
We are seeking a research tech to help with our human monoclonal antibody discovery efforts, with opportunity for further independent work. Basic science with translational outcomes. Please send the below link to anyone who might be interested. Thanks!
https://t.co/N4LjVNeIma
Check out this column piece by PMN Co-founder, Taylor Tibbs. She discusses how having a peer network can be a powerful force in relieving some of the difficulties associated with grad school and beyond.
@GannaMetzger, @wtjackson, et al. report surprising pH sensitivity findings in the EV-D68 lifecycle, different from poliovirus. @dapontediaz, @CameronLabUNC & @VogtVirusLab give thoughts on how EV-D68 and PV differ even though both can cause #AFM. #mBio https://t.co/lgvwABm3xO
So excited for #IDWeek2023 in Boston!!
Stay tuned for updates on @IDSAInfo’s newly minted LGBTQIA+ Interest Group, #ProudlyID!! We have plans for an informational session, booth time, and a night out this week!!
Can’t wait to see y’all!!! 🤓🥳🏳️🌈🦠🧫💊
@Anais_Ovalle@RMGmdID
💯
But also get the Global Entry ($100). Well worth it. Your time, not to mention sanity, has value. I don’t know how to properly assign that value, but it’s definitely worth this
Just a friendly reminder to all my postdoc friends "on the market" get your TSA Pre-check now. its good for 5 years and only 80$ (so like its basically free right?)